Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
ID: 344139Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $300K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/344139

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-021.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced the Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional), aimed at supporting early-stage investigators proposing innovative research in addiction genetics or epigenetics. This funding opportunity encourages the development of new methodologies and ideas that can advance the understanding and treatment of substance use disorders, with a focus on addressing significant scientific challenges in the field. Eligible applicants include a diverse range of organizations, such as higher education institutions and nonprofits, with budgets capped at $300,000 annually for up to five years. Applications are due by September 25, 2023, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-021.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-021.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA), has announced the Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional). This funding opportunity seeks to support early-stage investigators proposing innovative research in the field of addiction genetics or epigenetics, encouraging new methodologies and ideas that may advance understanding and treatment of substance use disorders. Applications are due by September 25, 2023, with subsequent cycles extending to September 2025. Eligible applicants include a range of organizations, from higher education institutions to nonprofits and government bodies, focusing on those who are considered Early Stage Investigators. Budgets are capped at $300,000 annually for up to five years, with specific application instructions requiring adherence to both NIH and program-specific criteria. Proposals must demonstrate significant scientific problems or barriers in addiction research, innovative approaches, and the potential for high impact, while applicants are required to share data openly post-research. The selection process involves rigorous peer review, emphasizing the scientific merits of applications and adherence to funding announcements. This program illustrates NIH's commitment to fostering breakthrough research in substance use disorders, aiming to cultivate the next generation of leaders in this critical domain.
    Similar Opportunities
    Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1), aimed at supporting early-stage investigators in conducting innovative research in the field of substance use disorders. This funding opportunity encourages applications for high-impact projects that do not require preliminary data, thereby fostering novel approaches to understanding and treating addiction. With a total budget of $3 million available annually over three fiscal years (FY 2024 - FY 2026), each award can provide up to $300,000 per year for a maximum of five years. Interested applicants must submit their proposals by August 9, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the official announcement link: https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-007.html.
    Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders" (R21/R33), aimed at supporting research projects that explore the genetic underpinnings of substance use disorders. This initiative encourages researchers to utilize innovative methodologies, such as CRISPR technologies, to validate addiction-relevant genes and characterize their roles in living organisms or human organoid systems, thereby enhancing the understanding of neurobiological mechanisms associated with addiction. The funding allows for up to $125,000 per year for the R21 phase over two years and up to $250,000 annually for the R33 phase over three years, with applications due by 5:00 PM local time on February 3, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-267.html.
    Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Avenir Award Program for Research on Substance Use Disorders and HIV, aimed at supporting early-stage investigators conducting innovative research at the intersection of HIV and substance use. This grant program encourages studies that align with NIH HIV/AIDS research priorities, focusing on reducing HIV transmission, optimizing therapies for co-occurring conditions, and enhancing treatment strategies for affected populations. Eligible applicants include a diverse range of institutions such as higher education institutions, non-profits, and government agencies, with a budget cap of $375,000 annually for up to four years, totaling $1.5 million in direct costs. Interested parties can find more information and application details at the provided NIH link, with the application deadline set for August 15, 2025.
    NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIDA Animal Genomics Program (U01), aimed at exploring the genetic and molecular factors associated with substance use disorders (SUD). This cooperative agreement encourages research that identifies genetic, genomic, and epigenetic variants influencing addictive behaviors and related comorbidities, utilizing diverse methodologies such as multi-omics and artificial intelligence. The program is open to a wide range of eligible applicants, including higher education institutions and nonprofit organizations, with no budget cap for proposals, although budgets should reflect actual project needs. Applications are due by February 12, 2027, with an opening date for submissions on January 11, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, a federal grant opportunity aimed at supporting innovative research proposals that address the intersection of HIV/AIDS and substance use disorders. This program seeks to fund exceptionally creative scientists who can propose high-impact studies that diverge significantly from existing research paths, with a focus on transformative approaches to prevention and treatment. The grant provides funding of up to $700,000 annually for a maximum duration of five years, with a submission deadline of August 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, aimed at supporting innovative research that intersects HIV and substance use disorders. This grant opportunity encourages creative scientists to propose high-impact studies that lead to new therapies and preventative strategies for HIV among drug users, emphasizing originality and alignment with NIH’s HIV/AIDS research priorities. The program allows for clinical trial proposals with a funding ceiling of $700,000 per year for up to five years, with applications due by August 15, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) to enhance research on substance use, addiction, and HIV through collaborative efforts among investigators. This program aims to integrate diverse new and early career researchers, particularly from underrepresented backgrounds, to develop innovative approaches and interdisciplinary projects that transform the scientific research landscape. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and government entities, with a maximum project period of five years and a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested parties should note that the application deadline is November 17, 2025, and can find more information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Mentored Clinical Scientist Development Program Award (K12), aimed at advancing research in substance use and substance use disorders (SUD). This funding opportunity supports clinician scientists through intensive mentorship and research experiences over a period of 3-4 years, requiring eligible scholars to hold a doctoral degree and dedicate at least 75% of their effort to research and career development. The program emphasizes the importance of fostering a diverse scientific workforce and requires applicants to include a recruitment plan to enhance diversity, alongside a structured career development and research plan aligned with NIDA’s mission. Interested applicants should note that the application submission window opens on February 6, 2024, with a funding ceiling of $750,000 per year for direct costs. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at NIDA's funding announcement.
    NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering the P50 Research Center of Excellence Grant Program to support innovative research in substance use and addiction. This program aims to establish multidisciplinary research centers that not only advance scientific knowledge but also serve as national resources for education and outreach within the drug abuse research community. The initiative encourages applications that focus on integrated themes rather than incremental work, with a budget limit of $10 million over five years and a maximum of 25% of direct costs allocated to pilot projects. Interested applicants should note that the submission process requires adherence to specific guidelines, including a Plan for Enhancing Diverse Perspectives (PEDP), and key deadlines extend until November 18, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.